Compare Domino's Pizza, Inc. (DPZ) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Domino's Pizza, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Domino's Pizza, Inc. trades at $309.36 (market cap $10.21B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Domino's Pizza, Inc. and State Street SPDR S&P Biotech ETF are close in size by market cap, and Domino's Pizza, Inc. pays a 2.58% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Domino's Pizza, Inc. for 106 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| DPZ | XBI | |
|---|---|---|
Market Cap | $10.21B | $10.11B |
Volume | 916,737 | 12,903,266 |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $438.42 | $169.55 |
52-Week Low | $282.89 | $104.99 |
Typical Hold Time | 106 Days | 38 Days |
Enterprise Value | $15.17B | — |
Dividend Yield | 2.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Domino's Pizza (DPZ) trades at $308.65, up 1.83% with a bullish technical signal despite recent earnings misses. The company maintains strong profitability with 11.86% net margin and $4.94B revenue, though faces debt concerns with negative shareholder equity. Recent news highlights dividend stability amid store closures and franchise challenges.
Outlook remains mixed with analyst consensus at Buy (50%) and $372 price target suggesting 21% upside, but high debt and competitive pressures pose risks. Earnings growth and debt management will be key catalysts for stock performance in the coming quarters.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite an oversold RSI reading. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive news flow around biotech catalysts. Recent articles highlight XBI's biotech focus versus broader healthcare ETFs, with expense ratio comparisons and volatility considerations.
The outlook remains cautious due to technical weakness and high volatility, though sector-specific catalysts like cancer vaccine developments and M&A activity provide potential upside. Key risks include sector volatility, regulatory uncertainty, and competitive ETF offerings with lower fees.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Domino's Pizza, Inc.
Domino's is a restaurant operator and franchiser with nearly 19,000 global stores across more than 90 international markets at the end of 2021. The firm generates revenue through the sales of pizza, wings, salads, and sandwiches at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 25 domestic (and five Canadian) dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for the firm's U.S. and Canadian restaurants. With roughly $17.7 billion in 2021 system sales, Domino's is the largest player in the global pizza market, ahead of Pizza Hut, Papa John's, and Little Caesars.
Read more on DPZ →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
